Publicacións en colaboración con investigadores/as de University of Oxford (11)

2024

  1. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

2023

  1. Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform

    Frontiers in Public Health, Vol. 11

2021

  1. Using Point of Care Testing to estimate influenza vaccine effectiveness in the English primary care sentinel surveillance network

    PLoS ONE, Vol. 16, Núm. 3 March

2020

  1. Integrating molecular point-of-care testing for influenza into primary care: A mixed-methods feasibility study

    British Journal of General Practice, Vol. 70, Núm. 697, pp. E555-E562

2019

  1. Feasibility of point-of-care testing for influenza within a national primary care sentinel surveillance network in England: Protocol for a mixed methods study

    JMIR Research Protocols, Vol. 8, Núm. 11

2017

  1. Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” (Vaccine (2017) 35(2) (395–402) (S0264410X16310404) (10.1016/j.vaccine.2016.11.009))

    Vaccine

  2. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial

    Vaccine, Vol. 35, Núm. 2, pp. 395-402

  3. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

    CMAJ, Vol. 189, Núm. 41, pp. E1276-E1285

2016

  1. Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age

    Pediatric Infectious Disease Journal

2013

  1. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

    Vaccine, Vol. 31, Núm. 42, pp. 4765-4774

2012

  1. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial

    JAMA, Vol. 307, Núm. 6, pp. 573-582